
Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.

Yehia Hashad, MD is an ophthalmologist and retinal specialist with more than 25 years of leadership experience in various ophthalmology global research and development roles, including his current role as the Executive Vice President of Research & Development and Chief Medical Officer at Bausch + Lomb.
Hashad obtained his Master of Science in Medical and Surgical Ophthalmology from Cairo University and a business degree from INSEAD in France. He previously served on the boards of The Glaucoma Research Foundation and the National Alliance of Eye and Vision Research and is currently a board adviser for the University of California Irvine Research Center.